Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
Spyre Therapeutics announced the completion of enrollment for all sub-studies in the SKYWAY Phase 2 basket trial of SPY072. The trial evaluates the anti-TL1A antibody in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).
Key figures
- Drug Name
- SPY072
- Phase Of Trial
- Phase 2
- Trial name
- SKYWAY
- Enrollment duration
- less than nine months
- Planned readouts 2026
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.